Hagens Berman Probes Aardvark Therapeutics Over ARD-101 Safety Disclosures
San Francisco – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has opened an investigation into Aardvark Therapeutics, Inc. (NASDAQ: AARD) over allegations that the company misled investors about the safety of its lead drug candidate ARD-101, ahead of an October 13, 2026 deadline for shareholders to seek lead plaintiff status in a pending securities class action.
Investors who bought Aardvark stock between February 13, 2025 and May 14, 2026 are covered by the class period
The lawsuit targets purchasers who acquired shares pursuant to Aardvark's February 13, 2025 initial public offering, as well as those who bought securities through May 14, 2026. The complaint alleges the company's offering documents failed to disclose that ARD-101 was significantly less safe than represented, including reversible cardiac observations such as QRS prolongation at above-target doses during clinical trials.